SynthesisFrontiers in oncology2026
Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phase III trials evaluating perioperative immune checkpoint inhibitors (ICIs) combined with chemotherapy for locally advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma have reported mixed efficacy results. We performed a systematic review and meta-analysis to synthesize the current evidence. Methods: We systematically searched for randomized phase III trials comparing perioperative ICI plus chemotherapy with chemotherapy alone. Only phase III RCTs were included to minimize bias and avoid overestimation from phase II studies (see Methods for rationale).Primary outcomes were pathological complete response (pCR). Secondary outcomes were grade ≥3 treatment-related adverse events (TRAEs). Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models for pCR due to clinical heterogeneity,fixed-effect models were used for safety as sensitivity. Heterogeneity was assessed using the I² statistic. Results: Three trials (DRAGON IV, MATTERHORN, KEYNOTE-585) involving 2,271 patients were included. The addition of ICIs significantly improved the pCR rate (random-effects OR 4.04, 95% CI 2.60 to 6.27; p < 0.00001; I² = 49%). Grade ≥3 TRAEs were numerically higher in the ICI-chemotherapy group (OR 1.61, 95% CI 0.96 to 2.71; p = 0.07; I² = 77%).Sensitivity analysis excluding the TKI-containing DRAGON IV trial attenuated the toxicity estimate (OR 1.23,95% CI 0.71-2.14;I Conclusion: The incorporation of ICIs into perioperative chemotherapy for locally advanced G/GEJ adenocarcinoma significantly enhances pathological response, albeit with an increased risk of grade ≥3 toxicities. These findings support perioperative ICI-chemotherapy as a promising and emerging strategy, pending confirmation from mature overall survival data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.